Maintenance rucaparib shows benefit in broader group of patients with pancreatic cancer
BRCA, HRR Deficiency, and PARP Inhibitors - ppt download
Cancer Trial Results
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
POLO trial for advanced pancreatic cancer: a | EurekAlert!
Trial results PARP inhibitors in pancreatic cancer | Download Scientific Diagram
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
Phase III POLO Trial - Slideset Download - Clin Onc June 2019 | CCO
Cancer Trial Results
POLO Trial Shows Maintenance Olaparib Improves PFS in Metastatic Pancreatic Cancer - The ASCO Post
New Homologous Recombination Deficiency Findings in Pancreatic Cancer Alter Treatment Focus
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Sotorasib in KRAS p.G12C-mutated Pancreatic Cancer
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Olaparib in Metastatic Pancreatic Cancer
Asco 2019 – Polo reveals an overall survival hole | Evaluate
POLO trial is back | OS is negative | But the manuscript is full SPIN CYCLE | Insane! - YouTube
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
ASCO GI 2021: Results From the Phase 3 POLO Trial
A trial of olaparib for pancreatic cancer that has spread (POLO) | Cancer Research UK
FORCE Blog | New PARP Inhibitor Approval for Pancreatic Cancer
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
NCCN Guidelines Updates: Pancreatic Cancer in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 5.5 (2019)
